Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 MedPacto: NDR Takeaways: Momentum Building up
2 Pre-Emptive Treatment May Be Superior to Reactive Treatment of Hand–Foot Reactions in mCRC
3 'Stivarga more potent in improving Asian patients' survival'
4 FDA expands approved use of Stivarga to treat liver cancer
5 Bayer looks for pharma growth in 2021 as new drugs start to take shape
6 Blueprint's Ayvakit fails to best Bayer's Stivarga
7 Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer
8 Can Stivarga crack the code? Bayer hunts for rare glioblastoma nod with 'Big 5' contender
9 First Patient Dosed in Trial of CS1001 Plus Stivarga for Advanced Tumors
10 Doctors Debate: Is Systemic or Liver-Directed Therapy Best for Hepatocellular Carcinoma?
11 Bayer Submits Supplemental New Drug Application for Stivarga® (regorafenib) for Advanced Liver Cancer
12 Cabometyx superior to Stivarga as second-line liver cancer treatment
13 Bayer's dominance in liver cancer challenged
14 Bristol-Myers Squibb, Bayer team up on Opdivo-Stivarga combo in colorectal cancer
15 Bayer to Showcase New Data from Evolving Oncology Portfolio at ESMO Virtual Congress 2020
16 Peripheral neuropathy reported in liver cancer drug Stivarga
17 Stivarga final NICE recommendation for hepatocellular carcinoma
18 Bayer's Stivarga wins NICE backing for advanced liver cancer
19 Stivarga to be tested as therapy for glioblastoma
20 Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
21 Real-World Study Confirms Safety of Regorafenib After Sorafenib in HCC
22 EMA clears Bayer's Stivarga for liver cancer
23 Bayer eyes liver cancer indication for Stivarga
24 FDA Grants Bayer Priority Review for Stivarga® (regorafenib) for the Second-Line Systemic Treatment of Liver Cancer
25 Finding the Optimal Dose of Regorafenib in Colorectal Cancer
26 Stivarga (Rcoloegorafenib) Approved For Colorectal Cancer Treatment
27 Biotech startup challenges Bayer's Stivarga patent
28 NICE turns down Bayer's Stivarga for liver cancer
29 Bayer's growth-driving quintet? Better make it a trio, thanks to Stivarga and Xofigo stall
30 NICE backing for Bayer's Stivarga in GIST
31 Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
32 Comparing Stivarga and Lonsurf in Metastatic Colorectal Cancer
33 Hope versus experience in glioblastoma
34 NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions
35 Dr. Lenz on Choosing Between Regorafenib and TAS-102 in CRC
36 Bayer, BMS, Ono team up to investigate Stivarga, Opdivo combo
37 Bayer's Stivarga® (regorafenib) Tablets Approved by US FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST
38 Bayer's Stivarga improves liver cancer survival rates, trial shows
39 FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors
40 Dr. Grothey on Choosing Between Regorafenib and TAS-102 in mCRC
41 Hutchison China MediTech Limited (HCM) Q4 2020 Earnings Call Transcript
42 Bayer, Apotex settle suit over cancer drug patent
43 Liver cancer patients barred from NHS access to Bayer's Stivarga
44 UPDATED: Bayer counts on Nexavar-Stivarga 'continuum' to protect its liver-cancer lead
45 Bayer gets US green light for colorectal cancer drug Stivarga
46 Regorafenib Showed Modest Activity in Ewing Sarcoma
47 Dr. Lenz on Later-Line Combo Approaches in CRC
48 Timeline on regorafenib (Stivarga) development
49 NICE recommends Stivarga ® for advanced unresectable HCC
50 Comparable Survival Observed With Regorafenib in HCC in Real-World Versus Clinical Settings
51 Bayer gets new Japanese approval for Stivarga
52 Dr. Kim on Efficacy and Next Steps of Phase 1/1b Study With Regorafenib + Nivolumab in CRC
53 Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers
54 Deciphera's Ripretinib In 2nd Line GIST: An Assessment
55 Regorafenib/Nivolumab Shows Modest Activity in MMR Proficient Advanced Refractory CRC
56 U.S. cancer doctors drop pricey drugs with little or no effect
57 Chemotherapy-Free Options Remain Unmet Need in Colorectal Cancer
58 Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
59 Coronavirus compounds trouble for Bayer
60 Raghav Discusses the Choice of Regorafenib or TAS-102 in Metastatic CRC
61 Bayer growth hope Stivarga boosts survival in liver cancer patients
62 Sutent: Side effects, cost, dosage, uses, alternatives, and more
63 Continued PFS, OS Benefit Seen With Ripretinib in Advanced GIST
64 Cabozantinib May Be a Match for Regorafenib in Second line Advanced HCC
65 Regorafenib Plus TAS-102 Demonstrates Clinically Meaningful Disease Control in mCRC
66 Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC
67 Bayer takes giant colon on tour to drum up colorectal cancer awareness
68 Regorafenib/Nivolumab Combo to Be Studied in Phase III Trial of Patients With MSS mCRC
69 Bayer receives approval in China for Stivarga
70 Exploring Current Treatment Options for Patients With HCC
71 Exploring Regorafenib and Nivolumab as Treatment for Colorectal Cancer
72 Colorectal Cancer Treatment Continues to Be Personalized
73 What Is the Best Treatment Option for Advanced Colorectal Cancer?
74 Blueprint's Ayvakit gets FDA no-go in new stomach cancer use but presses ahead in blood disorder
75 Dr. Grothey on Combination Therapies with Regorafenib and TAS-102 in CRC
76 Biotech targets Bayer growth hope Stivarga with IPR challenge
77 CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
78 Regorafenib Dose Escalation Superior in Metastatic CRC
79 North America to bank on Extensive research in the Colon Cancer Market from 2020 to 2030
80 Bristol-Myers' I-O star Opdivo steps up to challenge Bayer's Stivarga in liver cancer
81 Dose-Optimization Strategies Continue for Regorafenib in Colorectal Cancer With ReDOS Success
82 Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies
83 Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
84 Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
85 Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
86 As Roundup suits pile on, Bayer's drugs deliver a surprisingly good show
87 Regorafenib Doubles 12-Month Survival Compared with Lomustine in Recurrent GBM
88 Avapritinib Falls Short in VOYAGER Phase 3 GIST Trial
89 Xarelto and Eylea continue to dominate Bayer's pharma sales
90 New Immunotherapy Combinations Look to Create Maximum Velocity in Immune Systems Response to Cancer
91 Metastatic Colorectal Cancer Market Size Anticipated to Expand at a CAGR of 2.6% (2020-30) in the 7MM in the coming decade
92 Expert Explores Second-Line Treatment Options for Hepatocellular Carcinoma
93 Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC
94 FDA Grants Orphan Drug Designation to Ilixadencel to Treat Soft Tissue Sarcoma
95 Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial
96 Labour's promised Pharmac boost 'not enough'
97 Regorafenib OS Benefit Sustained in Updated HCC Findings
98 Factors to Consider When Prescribing 3L Colorectal Cancer Therapy
99 RESORCE Trial Analysis Shows Higher AFP Responses Achieved With Regorafenib in HCC
100 PFS Doubled With Regorafenib in Locally Advanced Biliary Tract Cancer